The MPP And Merck Partner For Molnupiravir In Lower-Income Countries
As MPP Looks To Further License Non-Exclusive Sublicenses To Manufacturers
Executive Summary
The Medicines Patent Pool has signed its first agreement to provide access for a COVID-19 medical technology with Merck & Co, to increase access of generic molnupiravir to 150 lower income countries.
You may also be interested in...
Medicines Patent Pool Facilitates Deals With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
MPP Facilitates Agreements With Seven Manufacturers For COVID-19 Antiviral
The Medicines Patent Pool has facilitated sublicenses with seven manufacturers to distribute generic versions of Shionogi’s oral COVID-19 antiviral ensitrelvir across low- and middle-income countries.
Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries
A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.